Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 9, 2013, Pages 1181-1192

  Jordán, Joaquín ^a   Ruíz Moreno, José M ^a  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Drug delivery; Intravitreal injection; Liposomes; Nanoparticles; Retina

Indexed keywords

ABC TRANSPORTER; AMINO ACID TRANSPORTER; BEVACIZUMAB; CELL PENETRATING PEPTIDE; CYCLODEXTRIN; GLUCOSE TRANSPORTER 1; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; NANOPARTICLE; POLYMER; RANIBIZUMAB; SCAVENGER RECEPTOR BI;

BLOOD EYE BARRIER; CATARACT; CORNEA EPITHELIUM; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; ENDOPHTHALMITIS; ENDOTHELIUM CELL; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; IONTOPHORESIS; MICROEMULSION; RETINA CAPILLARY; RETINA DETACHMENT; RETINA NEUROEPITHELIAL LAYER; REVIEW; UVEITIS;

BLOOD-RETINAL BARRIER; DRUG DELIVERY SYSTEMS; EPITHELIUM, CORNEAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RETINAL DISEASES;

EID: 84882331834     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.796928     Document Type: Review

References (105)

1. Jo DH, Kim JH. How to overcome retinal neuropathy: the fight against angiogenesis-related blindness. Arch Pharm Res 2010;33:1557-65
2. Kim JH, Park JA, Lee SW, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006;39:339-45
3. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004;78:715-21
4. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002;47(Suppl 1):S41-52
5. McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2000;2:289-313
6. Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 2002;10:535-8
7. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today 2009;14:306-15
8. Hoffman EA, Conley SM, Stamer WD, McKay BS. Barriers to productive transfection of trabecular meshwork cells. Mol Vis 2005;11:869-75
9. Jo DH, Lee TG, Kim JH. Nanotechnology and nanotoxicology in retinopathy. Int J Mol Sci 2011;12:8288-301
10. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004;15:897-900
11. Prow TW, Bhutto I, Kim SY, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340-9
12. Krug HF, Wick P. Nanotoxicology: an interdisciplinary challenge. Angew Chem Int Ed Engl 2011
13. Kim JH, Kim KW, Kim MH, Yu YS. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009;20:505101
14. Singh SR, Grossniklaus HE, Kang SJ, et al. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009;16:645-59
15. Suzuki T, Uno T, Chen G, Ohashi Y. Ocular distribution of intravenously administered micafungin in rabbits. J Infect Chemother 2008;14:204-7
16. Regnier A, Schneider M, Concordet D, Toutain PL. Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis. Am J Vet Res 2008;69:410-15
17. Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002;46:3719-23
18. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006;1:142-50
19. Korsvik C, Patil S, Seal S, Self WT. Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem Commun (Camb) 2007;1056-8
20. Heckert EG, Karakoti AS, Seal S, Self WT. The role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials 2008;29:2705-9
21. Cai X, Sezate SA, Seal S, McGinnis JF. Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria. Biomaterials 2012;33:8771-81
22. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84
23. Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491-504
24. Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009;11:1251-310
25. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001;50(Suppl 1):S69-89
26. Kranz H, Ubrich N, Maincent P, Bodmeier R. Physicomechanical properties of biodegradable poly(D,Llactide) and poly(D,L-lactide-coglycolide) films in the dry and wet states. J Pharm Sci 2000;89:1558-66
27. Bouissou C, Rouse JJ, Price R, van der Walle CF. The influence of surfactant on PLGA microsphere glass transition and water sorption: remodeling the surface morphology to attenuate the burst release. Pharm Res 2006;23:1295-305
28. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;102:23-38
29. Velazquez AJ, Carnahan MA, Kristinsson J, et al. New dendritic adhesives for sutureless ophthalmic surgical procedures: in vitro studies of corneal laceration repair. Arch Ophthalmol 2004;122:867-70
30. Grinstaff MW. Designing hydrogel adhesives for corneal wound repair. Biomaterials 2007;28:5205-14
31. Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12:1544-50
32. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7
33. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 2001;215:143-55
34. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001;52:5-16
35. Kurz D, Ciulla TA. Novel approaches for retinal drug delivery. Ophthalmol Clin North Am 2002;15:405-10
36. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. the ganciclovir implant study group. N Engl J Med 1997;337:83-90
37. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003;44:3562-9
38. Glybina IV, Kennedy A, Ashton P, et al. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci 2010;51:4243-52
39. Glybina IV, Kennedy A, Ashton P, et al. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci 2009;50:4847-57
40. Lindgren M, Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol Biol 2011;683:3-19
41. Cashman SM, Morris DJ, Kumar-Singh R. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol Ther 2003;8:130-42
42. Cashman SM, Sadowski SL, Morris DJ, et al. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol Ther 2002;6:813-23
43. Johnson LN, Cashman SM, Read SP, Kumar-Singh R. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res 2010;50:686-97
44. Read SP, Cashman SM, Kumar-Singh R. A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo. J Gene Med 2010;12:86-96
45. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103:3896-901
46. Rootman DS, Jantzen JA, Gonzalez JR, et al. Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Invest Ophthalmol Vis Sci 1988;29:1397-401
47. von Sallmann L. Iontophoretic introduction of atropine and scopolamine into the rabbit eye. Arch Ophthalmol 1943;29:9
48. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release 2006;110:479-89
49. Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bedside. Exp Eye Res 2004;78:751-7
50. Callegan MC, Hobden JA, O'Callaghan RJ, Hill JM. Ocular drug delivery: a comparison of transcorneal iontophoresis to corneal collagen shields. Int J Pharmal 1995;123:6
51. Loftsson T, Hreinsdottir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 2007;59:629-35
52. Hosoya K, Tomi M. Advances in the cell biology of transport via the inner blood-retinal barrier: establishment of cell lines and transport functions. Biol Pharm Bull 2005;28:1-8
53. Steuer H, Jaworski A, Elger B, et al. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci 2005;46:1047-53
54. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52
55. Mannermaa E, Vellonen KS, Ryhanen T, et al. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm Res 2009;26:1785-91
56. Tachikawa M, Toki H, Tomi M, Hosoya K. Gene expression profiles of ATP-binding cassette transporter A and C subfamilies in mouse retinal vascular endothelial cells. Microvasc Res 2008;75:68-72
57. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T. Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 2007;24:2281-96
58. Kennedy BG, Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis 2002;8:422-30
59. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. Pglycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85
60. Dey S, Anand BS, Patel J, Mitra AK. Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin Biol Ther 2003;3:23-44
61. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56
62. Majumdar S, Kansara V, Mitra AK. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J Ocul Pharmacol Ther 2006;22:231-41
63. Tomi M, Mori M, Tachikawa M, et al. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 2005;46:2522-30
64. Kumagai AK. Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab Res Rev 1999;15:261-73
65. Badr GA, Zhang JZ, Tang J, et al. Glut1 and glut3 expression, but not capillary density, is increased by cobalt chloride in rat cerebrum and retina. Brain Res Mol Brain Res 1999;64:24-33
66. Zhang JZ, Abbud W, Prohaska R, Ismail-Beigi F. Overexpression of stomatin depresses GLUT-1 glucose transporter activity. Am J Physiol Cell Physiol 2001;280:C1277-83
67. Shetty M, Loeb JN, Vikstrom K, Ismail-Beigi F. Rapid activation of GLUT-1 glucose transporter following inhibition of oxidative phosphorylation in clone 9 cells. J Biol Chem 1993;268:17225-32
68. Hosoya K, Minamizono A, Katayama K, et al. Vitamin C transport in oxidized form across the rat blood-retinal barrier. Invest Ophthalmol Vis Sci 2004;45:1232-9
69. Takata K, Kasahara T, Kasahara M, et al. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Invest Ophthalmol Vis Sci 1992;33:377-83
70. Zhang JZ, Gao L, Widness M, et al. Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 2003;44:4001-5
71. Xi X, Han J, Zhang JZ. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 2001;276:41029-34
72. Tachikawa M, Okayasu S, Hosoya K. Functional involvement of scavenger receptor class B, type I, in the uptake of alpha-tocopherol using cultured rat retinal capillary endothelial cells. Mol Vis 2007;13:2041-7
73. Tomi M, Hosoya K, Takanaga H, et al. Induction of xCT gene expression and L-cystine transport activity by diethyl maleate at the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 2002;43:774-9
74. Nakashima T, Tomi M, Katayama K, et al. Blood-to-retina transport of creatine via creatine transporter (CRT) at the rat inner blood-retinal barrier. J Neurochem 2004;89:1454-61
75. Tachikawa M, Takeda Y, Tomi M. Hosoya K. Involvement of OCTN2 in the transport of acetyl-L-carnitine across the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 2010;51:430-6
76. Tomi M, Terayama T, Isobe T, et al. Function and regulation of taurine transport at the inner blood-retinal barrier. Microvasc Res 2007;73:100-6
77. Tomi M, Kitade N, Hirose S, et al. Cationic amino acid transporter 1-mediated L-arginine transport at the inner blood-retinal barrier. J Neurochem 2009;111:716-25
78. Gerhart DZ, Leino RL, Drewes LR. Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience 1999;92:367-75
79. Hosoya K, Kondo T, Tomi M, et al. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 2001;18:1669-76
80. David J, Melamud A, Kesner L, et al. A novel calpain inhibitor for treatment of transient retinal ischemia in the rat. Neuroreport 2011;22:633-6
81. Hosoya K, Kyoko H, Toyooka N, et al. Evaluation of amino acid-mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents. Biol Pharm Bull 2008;31:2126-30
82. Hosoya K, Fujita K, Tachikawa M. Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate. Drug Metab Pharmacokinet 2008;23:285-92
83. Okamoto M, Akanuma S, Tachikawa M, Hosoya K. Characteristics of glycine transport across the inner blood-retinal barrier. Neurochem Int 2009;55:789-95
84. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35; e2
85. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98
86. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65; e5
87. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
88. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7
89. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11
90. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-7
91. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-82
92. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517-26
93. Englander M, Chen TC, Paschalis EI, et al. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol 2013;97:460-5
94. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-9
95. Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011;89:70-5
96. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007;27:541-51
97. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007;27:535-40
98. Meyer CH, Rodrigues EB, Michels S, et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010;26:491-5
99. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658-61
100. Sharei V, Hohn F, Kohler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010;20:174-9
101. Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010;150:558-61; e1
102. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29:313-18
103. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011;152:266-72
104. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9
105. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113